Abcellera Begin Period Cash Flow vs Stock Based Compensation Analysis

ABCL Stock

USD 2.99 0.04 1.32%

Abcellera Biologics financial indicator trend analysis is way more than just evaluating Abcellera Biologics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Abcellera Biologics is a good investment. Please check the relationship between Abcellera Biologics Begin Period Cash Flow and its Stock Based Compensation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Begin Period Cash Flow vs Stock Based Compensation

Begin Period Cash Flow vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Abcellera Biologics Begin Period Cash Flow account and Stock Based Compensation. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Abcellera Biologics' Begin Period Cash Flow and Stock Based Compensation is 0.82. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Abcellera Biologics, assuming nothing else is changed. The correlation between historical values of Abcellera Biologics' Begin Period Cash Flow and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Abcellera Biologics are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Begin Period Cash Flow i.e., Abcellera Biologics' Begin Period Cash Flow and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Abcellera Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Abcellera Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.At this time, Abcellera Biologics' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 1.68 this year, although the value of Tax Provision is projected to rise to (26.2 M).

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.8M	33.1M	30.9M	32.4M
Interest Income	3.3M	16.1M	42.2M	44.4M

Depreciation And Amortization Interest Income

Abcellera Biologics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.89	0.99	0.99	1.0	0.98	0.95	0.83	0.9	-0.69	0.96	0.89	0.79	0.97	0.96	1.0	0.71	0.99	0.83	0.98	0.81	0.78	0.99	1.0	0.82	-0.97
Short Long Term Debt Total	0.89		0.85	0.83	0.88	0.87	0.87	0.89	0.98	-0.33	0.95	0.78	0.46	0.96	0.81	0.87	0.3	0.82	0.71	0.94	0.94	0.85	0.91	0.88	0.89	-0.79
Other Current Liab	0.99	0.85		1.0	0.99	0.99	0.94	0.79	0.86	-0.73	0.95	0.91	0.82	0.95	0.95	0.99	0.75	0.98	0.84	0.97	0.78	0.74	0.99	0.99	0.79	-0.98
Total Current Liabilities	0.99	0.83	1.0		0.99	0.98	0.94	0.78	0.85	-0.75	0.93	0.89	0.84	0.94	0.97	0.99	0.79	0.99	0.82	0.95	0.74	0.74	0.98	0.99	0.78	-0.99
Total Stockholder Equity	1.0	0.88	0.99	0.99		0.98	0.95	0.82	0.9	-0.7	0.96	0.88	0.8	0.97	0.96	1.0	0.71	0.99	0.83	0.97	0.81	0.77	0.99	1.0	0.82	-0.98
Other Liab	0.98	0.87	0.99	0.98	0.98		0.92	0.8	0.85	-0.66	0.94	0.95	0.75	0.97	0.95	0.97	0.69	0.97	0.83	0.98	0.76	0.75	0.99	0.98	0.79	-0.94
Net Tangible Assets	0.95	0.87	0.94	0.94	0.95	0.92		0.93	0.88	-0.54	0.91	0.85	0.65	0.94	0.89	0.95	0.65	0.93	0.79	0.94	0.77	0.91	0.95	0.95	0.93	-0.97
Property Plant And Equipment Net	0.83	0.89	0.79	0.78	0.82	0.8	0.93		0.88	-0.21	0.84	0.76	0.34	0.89	0.73	0.81	0.35	0.76	0.68	0.88	0.78	0.99	0.85	0.82	1.0	-0.81
Current Deferred Revenue	0.9	0.98	0.86	0.85	0.9	0.85	0.88	0.88		-0.39	0.94	0.72	0.52	0.95	0.84	0.89	0.36	0.85	0.7	0.92	0.95	0.84	0.9	0.9	0.88	-0.82
Net Debt	-0.69	-0.33	-0.73	-0.75	-0.7	-0.66	-0.54	-0.21	-0.39		-0.58	-0.55	-0.99	-0.51	-0.73	-0.72	-0.91	-0.75	-0.59	-0.55	-0.36	-0.14	-0.63	-0.7	-0.2	0.74
Retained Earnings	0.96	0.95	0.95	0.93	0.96	0.94	0.91	0.84	0.94	-0.58		0.84	0.69	0.96	0.88	0.96	0.53	0.91	0.82	0.96	0.93	0.78	0.96	0.96	0.83	-0.9
Accounts Payable	0.89	0.78	0.91	0.89	0.88	0.95	0.85	0.76	0.72	-0.55	0.84		0.63	0.89	0.85	0.87	0.64	0.87	0.78	0.93	0.6	0.72	0.92	0.88	0.76	-0.85
Cash	0.79	0.46	0.82	0.84	0.8	0.75	0.65	0.34	0.52	-0.99	0.69	0.63		0.62	0.81	0.81	0.91	0.83	0.67	0.66	0.48	0.28	0.74	0.8	0.34	-0.82
Non Current Assets Total	0.97	0.96	0.95	0.94	0.97	0.97	0.94	0.89	0.95	-0.51	0.96	0.89	0.62		0.92	0.96	0.54	0.94	0.79	0.99	0.85	0.85	0.98	0.96	0.89	-0.91
Long Term Debt	0.96	0.81	0.95	0.97	0.96	0.95	0.89	0.73	0.84	-0.73	0.88	0.85	0.81	0.92		0.96	0.76	0.98	0.67	0.93	0.7	0.69	0.95	0.96	0.73	-0.94
Cash And Short Term Investments	1.0	0.87	0.99	0.99	1.0	0.97	0.95	0.81	0.89	-0.72	0.96	0.87	0.81	0.96	0.96		0.72	0.99	0.83	0.96	0.82	0.76	0.99	1.0	0.8	-0.98
Net Receivables	0.71	0.3	0.75	0.79	0.71	0.69	0.65	0.35	0.36	-0.91	0.53	0.64	0.91	0.54	0.76	0.72		0.79	0.59	0.58	0.22	0.32	0.67	0.72	0.35	-0.81
Common Stock Total Equity	0.99	0.82	0.98	0.99	0.99	0.97	0.93	0.76	0.85	-0.75	0.91	0.87	0.83	0.94	0.98	0.99	0.79		0.8	0.95	0.72	0.72	0.98	0.99	0.76	-0.98
Common Stock Shares Outstanding	0.83	0.71	0.84	0.82	0.83	0.83	0.79	0.68	0.7	-0.59	0.82	0.78	0.67	0.79	0.67	0.83	0.59	0.8		0.81	0.67	0.64	0.82	0.82	0.68	-0.8
Non Current Liabilities Total	0.98	0.94	0.97	0.95	0.97	0.98	0.94	0.88	0.92	-0.55	0.96	0.93	0.66	0.99	0.93	0.96	0.58	0.95	0.81		0.83	0.83	0.99	0.97	0.87	-0.92
Other Current Assets	0.81	0.94	0.78	0.74	0.81	0.76	0.77	0.78	0.95	-0.36	0.93	0.6	0.48	0.85	0.7	0.82	0.22	0.72	0.67	0.83		0.72	0.8	0.81	0.78	-0.71
Other Stockholder Equity	0.78	0.85	0.74	0.74	0.77	0.75	0.91	0.99	0.84	-0.14	0.78	0.72	0.28	0.85	0.69	0.76	0.32	0.72	0.64	0.83	0.72		0.8	0.77	0.99	-0.77
Total Liab	0.99	0.91	0.99	0.98	0.99	0.99	0.95	0.85	0.9	-0.63	0.96	0.92	0.74	0.98	0.95	0.99	0.67	0.98	0.82	0.99	0.8	0.8		0.99	0.85	-0.96
Net Invested Capital	1.0	0.88	0.99	0.99	1.0	0.98	0.95	0.82	0.9	-0.7	0.96	0.88	0.8	0.96	0.96	1.0	0.72	0.99	0.82	0.97	0.81	0.77	0.99		0.82	-0.98
Property Plant And Equipment Gross	0.82	0.89	0.79	0.78	0.82	0.79	0.93	1.0	0.88	-0.2	0.83	0.76	0.34	0.89	0.73	0.8	0.35	0.76	0.68	0.87	0.78	0.99	0.85	0.82		-0.81
Short Long Term Debt	-0.97	-0.79	-0.98	-0.99	-0.98	-0.94	-0.97	-0.81	-0.82	0.74	-0.9	-0.85	-0.82	-0.91	-0.94	-0.98	-0.81	-0.98	-0.8	-0.92	-0.71	-0.77	-0.96	-0.98	-0.81

Click cells to compare fundamentals

Abcellera Biologics Account Relationship Matchups

Abcellera Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.5M	1.0B	1.3B	1.5B	1.5B	989.6M
Short Long Term Debt Total	6.9M	6.1M	36.4M	82.3M	77.4M	39.0M
Other Current Liab	129.3K	52.6M	77.5M	76.3M	68.4M	50.4M
Total Current Liabilities	7.9M	103.5M	120.7M	118.3M	119.0M	87.2M
Total Stockholder Equity	10.3M	830.5M	1.0B	1.2B	1.2B	781.7M
Other Liab	1.3M	65.6M	134.0M	112.6M	129.5M	69.6M
Net Tangible Assets	2.7M	683.9M	829.5M	1.1B	1.2B	1.3B
Property Plant And Equipment Net	8.5M	17.9M	111.6M	217.3M	287.7M	302.1M
Current Deferred Revenue	3.2M	6.6M	7.5M	21.6M	19.0M	11.0M
Net Debt	(661.9K)	(588.0M)	(439.7M)	(304.3M)	(55.9M)	(58.7M)
Retained Earnings	(4.7M)	114.2M	267.7M	426.2M	279.8M	198.1M
Accounts Payable	1.6M	7.3M	32.0M	14.8M	25.5M	15.2M
Cash	7.6M	594.1M	476.1M	386.5M	133.3M	126.7M
Non Current Assets Total	10.8M	192.2M	388.8M	515.4M	616.1M	317.1M
Cash And Short Term Investments	7.6M	594.1M	723.0M	886.5M	760.6M	546.7M
Net Receivables	4.4M	213.2M	160.6M	38.6M	64.4M	89.0M
Common Stock Total Equity	5.1M	710.4M	722.4M	734.4M	844.5M	479.0M
Common Stock Shares Outstanding	154.1M	269.5M	318.3M	314.8M	289.2M	290.3M
Liabilities And Stockholders Equity	23.5M	1.0B	1.3B	1.5B	1.5B	989.6M
Non Current Liabilities Total	5.3M	71.5M	172.2M	189.3M	216.8M	120.7M
Capital Lease Obligations	3.1M	3.7M	36.4M	82.3M	77.4M	81.2M
Other Current Assets	1.8M	4.6M	21.2M	98.9M	45.9M	31.7M
Other Stockholder Equity	2.3M	5.9M	35.4M	74.1M	121.1M	127.1M
Total Liab	13.2M	175.0M	292.8M	307.6M	335.8M	208.0M
Net Invested Capital	6.5M	832.9M	1.0B	1.2B	1.2B	780.7M
Property Plant And Equipment Gross	8.5M	17.9M	121.4M	235.7M	318.3M	334.2M
Total Current Assets	12.6M	813.3M	929.8M	1.0B	872.0M	672.5M
Capital Stock	12.7M	710.4M	722.4M	734.4M	753.2M	540.0M
Net Working Capital	4.7M	709.8M	809.1M	907.2M	753.0M	585.3M
Short Term Debt	2.9M	865K	3.7M	5.6M	6.2M	4.0M
Common Stock	5.1M	710.4M	722.4M	734.4M	753.2M	537.3M
Property Plant Equipment	8.5M	17.9M	111.6M	217.3M	249.8M	262.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:

How To Invest In Abcellera

Details

Is Abcellera Stock a good investment?

Details

What is Abcellera Biologics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.459

Earnings Share

(0.61)

Revenue Per Share

0.112

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.13)

The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Abcellera Begin Period Cash Flow vs Stock Based Compensation Analysis

Begin Period Cash Flow vs Stock Based Compensation

Begin Period Cash Flow vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Stock Based Compensation

Abcellera Biologics fundamental ratios Correlations

Abcellera Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Abcellera Biologics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Short Long Term Debt	- 0.99	Total Current Liabilities
Short Long Term Debt	- 0.98	Net Invested Capital
Short Long Term Debt	- 0.98	Common Stock Total Equity
Short Long Term Debt	- 0.98	Cash And Short Term Investments
Short Long Term Debt	- 0.98	Total Stockholder Equity